THERAPY DOSSIER · th-60b9f83c93e7

Corilagin

Nutraceutical · No confident ChEMBL match; ellagitannin polyphenol

Evidence & regulatory context

Mechanism: No confident ChEMBL match; ellagitannin polyphenol
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23641818 ↗2013Reported benefit

Anti-inflammatory and anti-oxidative effects of corilagin in a rat model of acute cholestasis.

RatChemical/toxinSprague-DawleyMalen = 90 rats divided equally into five groups40 mg/kgAdministered before establishment of the cholestasis model

Model: Alpha-naphthylisothiocyanate (ANIT) 50 mg/kg given intragastrically to induce acute cholestasis

Corilagin improved living condition, liver histopathology and total and direct bilirubin, reduced myeloperoxidase, malondialdehyde and NF-kappaB translocation and increased superoxide dismutase and nitric oxide, with no effect on ALT or AST.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…